ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Biogen

<< Previous

Bullboard Posts

Next >>

Post by Gbathaton Sep 18, 2020 3:11pm

138 Views

Post# 31582735

Biogen

The elephant in the room on PMN310 delay is biogen.

Come March,come approval, biogen coffers will be overflowing and there will be no optics concerns for investing in PMN310. Nothing is more important than the FDA approval of aducanumab.

I'll continue loading up on the meantime... Hoping to hit 100k shares before then at an average pps of 0.11.

So keep bashing y'all!

<< Previous

Bullboard Posts

Next >>

New Pacific Metals delivers robust Silver Sand pre-feasibility study